Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.

Although responses to immune-modulating drugs in the body and the brain tend to be concordant, differences were found in MVD and T-cell content between these sites. Studies of these markers should be incorporated into prospective therapeutic clinical trials to determine their prognostic and predictive value.